AB InBev PureDraught™ Keg System Wins World Beverage Innovation Award
18.11.2019 17:20:00 EET | Business Wire | Press release
AB InBev and its Global Innovation and Technology Center (GITEC) announced that PureDraught™, a revolutionary one-way polymer keg system, won a World Beverage Innovation Award for “Best Manufacturing/Processing Innovation.” The honor was awarded at the BrauBeviale 2019 trade fair in Nuremberg, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191118005495/en/
PureDraught™ keeps beer fresher up to four times longer than a traditional steel keg and reduces the carbon footprint of shipping beer -- all while offering more versatility and variety for bar and restaurant owners. (Photo: Business Wire)
PureDraught™ keeps beer fresher up to four times longer than a traditional steel keg and reduces the carbon footprint of shipping beer -- all while offering more versatility and variety for bar and restaurant owners.
Using a custom-molded, double-walled, bottle-in-bottle polymer keg, PureDraught allows air or gas to be fed into the outer bottle, which keeps its shape and pushes the beer out of the inner bottle. This innovation prevents any air or dispense gas from touching the beer, allowing the beer to remain fresh for 30 days after being tapped instead of just a week.
In addition, PureDraught comes in 6L, 12L and 18L sizes rather than the standard 30L or larger steel keg size, allowing for more flexibility and less wasted product by bar and restaurant owners. The kegs can be stored and dispensed from upright or on their side on a shelf, making them more versatile.
“We are honored that our research and technological innovation for PureDraught has been recognized by the prestigious World Beverage Innovation Awards,” said Rodrigo Sozo, Vice President of AB InBev GITEC. “This is a validation of the hard work and passion of our team as they set out to develop a transformational innovation for draught beer, including superior quality, less carbon footprint and more variety of beers on tap. We are also excited about how the technology platform creates new consumer experiences for all types of occasions of draught beer consumption.”
There are no additional costs for a bar to use the PureDraught system or the beer in the one-way kegs, and in most markets, the system’s custom keg coupler is provided and connected to a bar’s existing beer and gas lines by AB InBev free of charge.
Currently, PureDraught is in use with AB InBev brands in more than eight countries, including the U.S., Mexico, Brazil, China, Italy, Japan and South Korea as well as additional areas of Europe and Africa, providing the best pour of brands like Stella Artois. For more information, including how to convert your establishment to PureDraught, visit https://puredraught.com/.
About AB InBev GITEC
The Global Innovation and Technology Center (GITEC) at AB InBev is the hub of innovation for the company, working across teams and the company’s more than 500 brands to develop new products, processes and technologies. Driven by a team of more than 120 passionate R&D talents from more than 20 countries, GITEC works to revolutionize packaging, make the brewing process more efficient and sustainable, create breakthroughs in how our beers are delivered and dispensed, and to offer new tasting and consumer experiences.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191118005495/en/
Contact information
Media Contact:
Shawn Malayter
Greenhouse Partners
872-267-2636
smalayter@greenhousepartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
